Overview

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

Status:
Not yet recruiting

Trial end date:
2027-10-30

Target enrollment:

Participant gender:

Summary

This is an open-label, multi-center Phase II study of fluzoparib combined with bevacizumab for maintenance therapy after first-line platinum-containing chemotherapy in patients with BRCA wild-type advanced ovarian cancer. The primary objective is to evaluate median progression free survival of fluzoparib plus bevacizumab.

Phase:

Phase 2

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Angiogenesis Inhibitors
Bevacizumab
Fluzoparib
Poly(ADP-ribose) Polymerase Inhibitors